Search our Database of Scientific Publications and Authors

I’m looking for a

    8225 results match your criteria Breast cancer research and treatment[Journal]

    1 OF 165

    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat 2017 Nov 17. Epub 2017 Nov 17.
    Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3318 AT, Dordrecht, The Netherlands.
    Purpose: Body composition parameters including low muscle mass, muscle attenuation (which reflects muscle quality) and adipose tissue measurements have emerged as prognostic factors in cancer patients. However, knowledge regarding the possibility of excessive muscle loss during specific systemic therapies is unknown. We describe the changes in body composition and muscle attenuation (MA) during taxane- and anthracycline-based regimens and its association with overall survival (OS) in metastatic breast cancer patients. Read More

    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat 2017 Nov 15. Epub 2017 Nov 15.
    Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, Cairo, 11566, Egypt.
    Objectives: To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer.

    Methods: Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) according to both anatomical and prognostic stages. Read More

    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat 2017 Nov 14. Epub 2017 Nov 14.
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
    Purpose: Exercise training is an effective and safe way to counteract cancer-related fatigue (CRF) and to improve health-related quality of life (HRQoL). High-intensity interval training has proven beneficial for the health of clinical populations. The aim of this randomized controlled trial was to compare the effects of resistance and high-intensity interval training (RT-HIIT), and moderate-intensity aerobic and high-intensity interval training (AT-HIIT) to usual care (UC) in women with breast cancer undergoing chemotherapy. Read More

    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat 2017 Nov 14. Epub 2017 Nov 14.
    Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
    In the original publication of the article, the acknowledgment section was missed out inadvertently. The acknowledgement section is below. Read More

    21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Breast Cancer Res Treat 2017 Nov 11. Epub 2017 Nov 11.
    National Surgical Adjuvant Breast and Bowel Project (NSABP) (NSABP Legacy trials are now a part of the NRG Oncology portfolio), Pittsburgh, PA, USA.
    Background: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen.

    Methods: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients. Read More

    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat 2017 Nov 11. Epub 2017 Nov 11.
    School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.
    Purpose: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle-aged and older breast cancer survivors. Read More

    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat 2017 Nov 11. Epub 2017 Nov 11.
    Ralph Lauren Centre for Breast Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
    Purpose: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy.

    Methods: Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear. Read More

    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat 2017 Nov 11. Epub 2017 Nov 11.
    Department of Clinical and Experimental Medicine, and Department of Oncology, Linköping University, Linköping, Sweden.
    Purpose: Deregulated PI3K/mTOR signals can promote the growth of breast cancer and contribute to endocrine treatment resistance. This report aims to investigate raptor and its intracellular localization to further understand its role in ER-positive breast cancer.

    Methods: Raptor protein expression was evaluated by immunohistochemistry in 756 primary breast tumors from postmenopausal patients randomized to tamoxifen or no tamoxifen. Read More

    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat 2017 Nov 10. Epub 2017 Nov 10.
    Department of Psychology& Neuroscience, University of Colorado Boulder, Muenzinger D244, 345 UCB, Boulder, CO, 80309-0345, USA.
    Purpose: To examine DNA methylation as a mechanism linking diet, physical activity, weight status, and breast cancer risk.

    Methods: Insufficiently active women of varying weight status, without a history of cancer, completed a maximal exercise test, clinical measurement of height and weight, and a dietary intake measure. They also provided blood samples, which were analyzed to ascertain average methylation of candidate genes related to breast cancer (BRCA1, RUNX3, GALNT9, and PAX6) and inflammation (TLR4 and TLR6). Read More

    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat 2017 Nov 10. Epub 2017 Nov 10.
    School of Public Health, Cancer Prevention Research Centre, The University of Queensland, Brisbane, Australia.
    In the original publication of the article, under the heading Discussion, 1st paragraph, the sentence that reads as, "Nonetheless, our observed improvements of over 50% for OS and over 30% for DFS (HRs: 0.45 and 0.66, respectively) are consistent with results from other available studies" should read as "Nonetheless, our observed improvements of over 50% for OS and DFS (HRs: 0. Read More

    Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Breast Cancer Res Treat 2017 Nov 9. Epub 2017 Nov 9.
    Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, 160 East 34th Street, New York, NY, 10016, USA.
    Background And Purpose: Resistance to endocrine therapies in hormone receptor (HR)-positive breast cancer is a significant challenge. Prior studies have shown that low-dose oral cyclophosphamide can transiently deplete regulatory T cells (Tregs) and improve anti-tumor immunity. We investigated the combination of exemestane with cyclophosphamide in patients with advanced HR-positive breast cancer and assessed changes in circulating immune cell subsets. Read More

    Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat 2017 Nov 9. Epub 2017 Nov 9.
    Division of Hematology/Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Campus, PO Box 7305, Chapel Hill, NC, 27599-7305, USA.
    Purpose: Ensuring and measuring adherence to prescribed exercise regimens are fundamental challenges in intervention studies to promote exercise in adults with cancer. This study reports exercise adherence in women who were asked to walk 150 min/week throughout chemotherapy treatment for early breast cancer. Participants were asked to wear a Fitbit(TM) throughout their waking hours, and Fitbit steps were uploaded directly into study computers. Read More

    Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Breast Cancer Res Treat 2017 Nov 8. Epub 2017 Nov 8.
    Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Podium B Room 404, Washington, 20007, DC, USA.
    Purpose: Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-related death among women. Given the availability of approved therapies and abundance of phase II and III clinical trials, historically few BC patients have been referred for consideration of participation on a phase I trial. We were interested in determining whether clinical benefit rates differed in patients with BC from other patients enrolled in phase I trials. Read More

    Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
    Breast Cancer Res Treat 2017 Nov 8. Epub 2017 Nov 8.
    Women's College Research Institute, 76 Grenville Street, Toronto, ON, M5S 1B1, Canada.
    Background: Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of epithelial cells which is confined within the basement membrane of the mammary ductal-lobular system. It is of interest to determine to what extent the potential to metastasize increases for DCIS patients when the basement membrane is breached (i.e. Read More

    BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Breast Cancer Res Treat 2017 Nov 7. Epub 2017 Nov 7.
    Laboratory of Genomics and Molecular Biology, CIPE - A. C. Camargo Cancer Center, São Paulo, Brazil.
    Purpose: BRCA1 germline mutation is closely associated with triple-negative breast cancer. BRCA deficiency leads to impaired DNA repair and tumor development, and understanding this deficiency, in both hereditary and sporadic scenarios, is of great clinical and biological interest. Here, we investigated germline or somatic events that might lead to BRCA1 impairment in triple-negative breast cancer. Read More

    Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat 2017 Nov 7. Epub 2017 Nov 7.
    Manchester Centre for Genomic Medicine, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.
    Purpose: Previous research assessing the impact of pregnancy and age at first pregnancy on breast cancer risk in BRCA1 and BRCA2 mutation carriers has produced conflicting results, with some studies showing an increased risk following early first pregnancy in contrast to the reduced risk in the general population of women. The present study addresses these inconsistencies.

    Methods: Female BRCA1 and BRCA2 carriers from North West England were assessed for breast cancer incidence prior to 50 years of age comparing those with an early first full-term pregnancy (< 21 years) to those without a full-term pregnancy. Read More

    Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Breast Cancer Res Treat 2017 Nov 7. Epub 2017 Nov 7.
    Department of Radiology, Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, 3155 Porter Drive, MC5483, Palo Alto, CA, 94304, USA.
    Purpose: 27-hydroxycholesterol (27HC), an endogenous selective estrogen receptor modulator (SERM), drives the growth of estrogen receptor-positive (ER+) breast cancer. 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D, is known to inhibit expression of CYP27B1, which is very similar in structure and function to CYP27A1, the synthesizing enzyme of 27HC. Therefore, we hypothesized that 1,25(OH)2D may also inhibit expression of CYP27A1, thereby reducing 27HC concentrations in the blood and tissues that express CYP27A1, including breast cancer tissue. Read More

    Breast cancer-related paraneoplastic neurologic disease.
    Breast Cancer Res Treat 2017 Nov 7. Epub 2017 Nov 7.
    Department of Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA.
    Purpose: Paraneoplastic neurologic disease (PND) is an aberrant immune-mediated response against the nervous system triggered by malignancy. Given the rarity, a paucity of data describing breast cancer-related PND (BC-PND) exists; we sought to further examine this specific patient population.

    Methods: We retrospectively identified patients at our institution from 1997 to 2016 with BC-PND. Read More

    Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Breast Cancer Res Treat 2017 Nov 7. Epub 2017 Nov 7.
    Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine and Baylor St. Luke's Medical Center, BCM 600, One Baylor Plaza, Houston, TX, 77030, USA.
    Purpose: Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.

    Patients And Methods: Baseline tumor samples from patients with HER2-positive breast cancer enrolled in TBCRC006 (NCT00548184), a 12-week neoadjuvant clinical trial with lapatinib plus trastuzumab [plus endocrine therapy for estrogen receptor (ER)-positive tumors], were assessed for PTEN status by immunohistochemistry and PIK3CA mutations by sequencing. Read More

    Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Breast Cancer Res Treat 2017 Nov 6. Epub 2017 Nov 6.
    School of Population and Public Health, University of British Columbia, V2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.
    Background: Adjuvant endocrine therapy (AET) significantly reduces recurrence and mortality in women with breast cancer (BrCa). Despite the efficacy of AET in improving BrCa outcomes, up to 50% of women do not adhere to prescribed AET regimens. While numerous demographic and clinical predictors influence adherence and persistence, few studies have identified the patient-reported factors that influence AET adherence and persistence. Read More

    The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
    Breast Cancer Res Treat 2017 Nov 6. Epub 2017 Nov 6.
    Department of Physical Therapy, University of British Columbia, 212-2177 Wesbrook Mall, Vancouver, V6T 1Z3, Canada.
    Purpose: In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms.

    Methods: Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vigorous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Read More

    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast Cancer Res Treat 2017 Nov 4. Epub 2017 Nov 4.
    Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
    Purpose: Prospective information regarding the tolerability and efficacy of endocrine therapy (ET) alone and in combination with targeted agents in older patients in the metastatic setting is limited. This review summarizes available trial data in this population.

    Methods: We searched PubMed for Phase 2 or 3 trials with age-stratified patient cohorts (≥ 65 vs. Read More

    Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.
    Breast Cancer Res Treat 2017 Nov 3. Epub 2017 Nov 3.
    Stefanie Spielman Comprehensive Breast Center, The Ohio State University, Columbus, OH, USA.
    Purpose: Aromatase inhibitor (AI)-induced joint symptoms negatively impact drug adherence and quality of life in breast cancer survivors. Mechanisms underlying symptoms may include inflammation. It is hypothesized that n - 3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory properties and may reduce symptoms. Read More

    Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Breast Cancer Res Treat 2017 Nov 2. Epub 2017 Nov 2.
    Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
    Purpose: To determine if women with breast cancer that undergo fertility preservation (FP), with or without hormonal stimulation, present with an increased risk of breast cancer recurrence.

    Methods: A matched cohort study on women with breast cancer attempting to ensure FP in Stockholm from 1999 to 2013 [exposed women (n = 188), age-matched unexposed controls (n = 378)] was designed using the Stockholm regional data from the Swedish National Breast Cancer Quality Register. Breast cancer relapse rates [incidence rate ratio (IRR)] and 95% confidence interval (CI) were estimated using Cox regression and adjusted for potential confounding factors. Read More

    CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.
    Breast Cancer Res Treat 2017 Nov 1. Epub 2017 Nov 1.
    Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
    Purpose: While the role of natural killer (NK) cells in breast cancer therapy has been investigated, little information is known about NK cell function and presence in nonmalignant and premalignant breast tissue. Here, we investigate and quantify NK cell marker CD56 and activating ligand MICA in breast tissue with benign breast disease.

    Methods: Serial tissue sections from 88 subjects, 44 with benign breast disease (BBD) who remained cancer-free, and 44 with BBD who later developed cancer, were stained with H&E, anti-MICA, and anti-CD56. Read More

    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Breast Cancer Res Treat 2017 Oct 30. Epub 2017 Oct 30.
    Oniris, Nantes Atlantic College of Veterinary Medicine Food Science and Engineering, Animal Cancers, Models for Research in Comparative Oncology (AMaROC) Research Unit, Site de La Chantrerie, 102 Route de Gachet, CS40706, 44307, Nantes, France.
    Purpose: Dogs have been proposed as spontaneous animal models of human breast cancer, based on clinicopathologic similarities between canine and human mammary carcinomas. We hypothesized that a better knowledge of the natural history and prognostic factors of canine invasive mammary carcinomas would favor the design of preclinical trials using dogs as models of breast cancer.

    Methods: The 2-year outcome of 350 female dogs with spontaneous invasive mammary carcinoma was studied. Read More

    The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Breast Cancer Res Treat 2017 Oct 30. Epub 2017 Oct 30.
    Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
    Purpose: The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. Read More

    The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
    Breast Cancer Res Treat 2017 Oct 30. Epub 2017 Oct 30.
    Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Ramat Gan, Israel.
    Background: Hereditary breast cancer is predominantly associated with germline mutations in the BRCA1 or BRCA2 genes. A few recurring mutations in these genes were reported in ethnically diverse Jewish populations. Since 2013, most oncogenetic laboratories in Israel adopted a two-step approach for BRCA1/2 genotyping, where the first step is genotyping for 14 seemingly recurring mutations-first-pass genotyping. Read More

    Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery.
    Breast Cancer Res Treat 2017 Oct 28. Epub 2017 Oct 28.
    Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
    Purpose: A majority of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then face a risk of ipsilateral breast tumor recurrence (IBTR) which can be either recurrence of DCIS or invasive breast cancer. We developed a score to provide individualized information about IBTR risk to guide treatment decisions.

    Methods: Data from 2762 patients treated with BCS for DCIS at centers within the National Comprehensive Cancer Network (NCCN) were used to identify statistically significant non-treatment-related predictors for 5-year IBTR. Read More

    Sensation of the autologous reconstructed breast improves quality of life: a pilot study.
    Breast Cancer Res Treat 2017 Oct 25. Epub 2017 Oct 25.
    Department of Plastic Surgery, Maastricht University Medical Center +, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
    Purpose: The number of breast cancer survivors continues to grow. Due to refinements in operating techniques, autologous breast reconstruction has become part of standard care. Impaired sensation remains a debilitating side effect with a significant impact on the quality of life. Read More

    Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat 2017 Oct 25. Epub 2017 Oct 25.
    Department of Surgery and Cancer, Imperial College London, London, W12 0NN, UK.
    In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: 'The study was coordinated by the Imperial Clinical Trials Unit-Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. Read More

    The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.
    Breast Cancer Res Treat 2017 Oct 24. Epub 2017 Oct 24.
    Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, Detroit, MI, 48201, USA.
    Purpose: Statins have been postulated to have chemopreventive activity against breast cancer. We evaluated whether germline genetic polymorphisms modified the relationship between statins and breast cancer risk using data from the Women's Health Initiative. We evaluated these interactions using both candidate gene and agnostic genome-wide approaches. Read More

    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Breast Cancer Res Treat 2017 Oct 23. Epub 2017 Oct 23.
    Sarah Cannon Research Institute, Nashville, TN, USA.
    Purpose: Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC.

    Methods: In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after standard-of-care therapy received avelumab intravenously 10 mg/kg every 2 weeks. Read More

    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Breast Cancer Res Treat 2017 Oct 23. Epub 2017 Oct 23.
    CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
    Purpose: Relevant animal models of human breast cancer are currently needed, especially for the aggressive triple-negative breast cancer subtype. Recent studies and our results (Part 1) indicate that spontaneous canine invasive mammary carcinomas (CMCs) resemble human breast cancer by clinics and pathology as well as behavior and prognostic indicators. We hypothesized that the current molecular classifications of human breast cancer, used for therapeutic decision, could be relevant to dogs. Read More

    Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat 2017 Oct 23. Epub 2017 Oct 23.
    School of Public Health, Cancer Prevention Research Centre, The University of Queensland, Brisbane, Australia.
    Purpose: The Exercise for Health trials were randomised, controlled trials designed to evaluate an 8-month pragmatic exercise intervention, commencing 6 weeks post-surgery for women with newly diagnosed breast cancer residing in urban or rural/regional Australia. For these exploratory analyses, the primary and secondary outcomes were overall survival (OS) and disease-free survival (DFS), respectively.

    Methods: Consenting urban- (n = 194) and rural/regional-residing women (n = 143) were randomised to exercise (intervention delivered face-to-face or by telephone) or usual care. Read More

    Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat 2017 Oct 22. Epub 2017 Oct 22.
    Sarah Cannon Research Institute, 250 25th Avenue North #100, Nashville, TN, 37203, USA.
    Purpose: Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2- advanced breast cancer.

    Methods: 668 postmenopausal women with HR+, HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021); 295 patients were aged ≥ 65 years. Patients were randomized to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2. Read More

    The importance of early detection of calcifications associated with breast cancer in screening.
    Breast Cancer Res Treat 2017 Oct 17. Epub 2017 Oct 17.
    Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, The Netherlands.
    Purpose: The aim of this study was to assess how often women with undetected calcifications in prior screening mammograms are subsequently diagnosed with invasive cancer.

    Methods: From a screening cohort of 63,895 women, exams were collected from 59,690 women without any abnormalities, 744 women with a screen-detected cancer and a prior negative exam, 781 women with a false positive exam based on calcifications, and 413 women with an interval cancer. A radiologist identified cancer-related calcifications, selected by a computer-aided detection system, on mammograms taken prior to screen-detected or interval cancer diagnoses. Read More

    Serum selenium levels predict survival after breast cancer.
    Breast Cancer Res Treat 2017 Oct 17. Epub 2017 Oct 17.
    Women's College Research Institute, 76 Grenville Street, 6th Floor, Toronto, ON, M5S 1B2, Canada.
    Background: Studies have reported an inverse relationship between serum selenium levels and cancer incidence, but the impact of low serum selenium status on survival after a diagnosis of breast cancer has not been established.

    Methods: We obtained a blood sample from 546 women diagnosed with a first primary invasive breast cancer between 2008 and 2015 in the region of Szczecin, Poland. Blood was collected after diagnosis, but prior to treatment. Read More

    Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Breast Cancer Res Treat 2017 Oct 16. Epub 2017 Oct 16.
    Swedish Cancer Institute, Seattle, WA, USA.
    Background: Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation and survival over time have not been adequately described.

    Methods: A retrospective cohort study, 1990-2010, with follow up through 2015 of dnMBC patients (stage IV at diagnosis) and rMBC patients with subsequent distant metastatic recurrence (stage I-III initial diagnosis) [dnMBC = 247, rMBC = 911)]. Analysis included Chi squared tests of categorical variables, Kaplan-Meier survival estimates, and Cox proportional adjusted hazard ratios (HzR) and 95% confidence intervals (CI). Read More

    Clinical implications of germline mutations in breast cancer: TP53.
    Breast Cancer Res Treat 2017 Oct 16. Epub 2017 Oct 16.
    East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.
    Purpose: This review describes the prevalence of germline TP53 mutations, the risk of breast cancer and other cancers in mutation carriers and management implications for women with breast cancer and unaffected women.

    Methods: Literature review of English language papers available through PubMed.

    Results: Women who carry germline mutations in the TP53 gene have a very high risk of breast cancer of up to 85% by age 60 years. Read More

    A systematic review of flap fixation techniques in reducing seroma formation and its sequelae after mastectomy.
    Breast Cancer Res Treat 2017 Oct 16. Epub 2017 Oct 16.
    Department of Surgery, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
    Background: Seroma formation is a common complication after mastectomy. This review aims to elucidate which surgical techniques are most effective in reducing the dead space and therefore seroma formation in patients undergoing mastectomy.

    Methods: A literature search was performed to identify clinical studies comparing any form of flap fixation to conventional closure technique in patients undergoing mastectomy with or without axillary clearance. Read More

    Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
    Breast Cancer Res Treat 2017 Oct 13. Epub 2017 Oct 13.
    Outpatient-Centre for Interdisciplinary Oncology and Haematology, Wirthstrasse 11c, 79110, Freiburg, Germany.
    Purpose: There is an ongoing discussion about 'undertreatment' of breast cancer in elderly patients. Due to low accrual into clinical trials, level 1 evidence is scarce. We report prospective data of elderly patients with breast cancer treated by medical oncologists in Germany. Read More

    Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat 2017 Oct 13. Epub 2017 Oct 13.
    Department of Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
    Purpose: We investigated the usefulness of abbreviated breast MRI (AB-MRI), including fat-suppressed T2-weighted imaging, pre- and postcontrast image acquisition, and subtracted maximum-intensity projection imaging, for the screening of women with a history of breast cancer surgery.

    Methods: Between October 2014 and March 2016, a total of 799 AB-MRI examinations were performed for 725 women with a history of breast cancer surgery. The image acquisition time was 8. Read More

    Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically.
    Breast Cancer Res Treat 2017 Oct 13. Epub 2017 Oct 13.
    Romagna Cancer Registry, Romagna Cancer Institute (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS), Meldola, Forlì, Italy.

    A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Breast Cancer Res Treat 2017 Oct 13. Epub 2017 Oct 13.
    Canadian Cancer Trials Group, Kingston, ON, Canada.
    Background: Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents. This multicentre, randomized, phase II trial was undertaken to evaluate the efficacy and safety of adding pelareorep to paclitaxel for patients with metastatic breast cancer (mBC).

    Methods: Following a safety run-in of 7 patients, 74 women with previously treated mBC were randomized either to paclitaxel 80 mg/m(2) intravenously on days 1, 8, and 15 every 4 weeks plus pelareorep 3 × 10(10) TCID50 intravenously on days 1, 2, 8, 9, 15, and 16 every 4 weeks (Arm A) or to paclitaxel alone (Arm B). Read More

    Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
    Breast Cancer Res Treat 2017 Oct 12. Epub 2017 Oct 12.
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Central Hospital, 1-1, Kanokoden, Chikusa, Nagoya, 464-8681, Japan.
    Purpose: Circulating tumor cells (CTCs) can provide a potentially minimal invasive source for monitoring chemotherapeutic effects. However, detailed in vivo dynamics of CTC after chemotherapy remain largely unknown.

    Methods: We monitored CTC number and morphology early after chemotherapy using a newly developed cytology-based CTC detection device and triple-negative breast cancer mouse CTC models with spontaneous lung metastatic potential. Read More

    1 OF 165